Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retrovirus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Retrovirus. Displaying page 1 of 1.
    EudraCT Number: 2007-007839-33 Sponsor Protocol Number: IN-IT-177-0113 Start Date*: 2008-01-25
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: Adherence to a one pill, once-a-day antiretroviral regimen
    Medical condition: patient HIV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038997 Retroviral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014316-35 Sponsor Protocol Number: 576/09 Start Date*: 2009-08-26
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Phase IIb pilot study for the evaluation of the safety and the feasibility of treatment simplification to tenofovir+emtricitabina+raltegravir or to lamivudine+abacavir+raltegravir in patients with ...
    Medical condition: HIV
    Disease: Version SOC Term Classification Code Term Level
    12.0 10038997 Retroviral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001072-22 Sponsor Protocol Number: T51/2015 Start Date*: 2016-01-26
    Sponsor Name:Turku University Hospital
    Full Title: Clinical and virological efficacy of pegylated interferon alpha in the treatment of rhinovirus infection in patients with primary hypogammaglobulinemia: randomized controlled trial
    Medical condition: Rhinovirus infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10039107 Rhinovirus infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004938-42 Sponsor Protocol Number: EHRVI Start Date*: 2013-03-01
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Experimental Human Rhinovirus Infection, a randomized placebo-controlled pilot study
    Medical condition: Viral infections in general, and the "common cold" induced by HRV-16 in particular.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061494 Rhinovirus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-001925-27 Sponsor Protocol Number: 06-MI-04 Start Date*: 2009-10-05
    Sponsor Name:Great Ormond Street Hospital For Children NHS Trust
    Full Title: Phase I/II clinical trial of T cell suicide gene therapy following haploidentical stem cell transplantation
    Medical condition: Graft-versus-host disease (GVHD) resulting from haploidentical bone marrow or blood stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000865-21 Sponsor Protocol Number: AI424-136 Start Date*: 2005-09-28
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir ...
    Medical condition: HIV-infected individuals
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) ES (Completed) LV (Completed) DE (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001895-11 Sponsor Protocol Number: AI424-138 Start Date*: 2006-02-07
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir with Lopinavir/ritonavir, Each in Combination with Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment...
    Medical condition: HIV-1 Infected Treatment Naive Subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) BE (Completed) PT (Completed) ES (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004867-38 Sponsor Protocol Number: AUTO-LT1 Start Date*: 2018-05-18
    Sponsor Name:Autolus Limited
    Full Title: Long-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.
    Medical condition: Potential malignancy in patients who received treatment with Autolus' CAR T cell therapy.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003654-29 Sponsor Protocol Number: 1100.1486 Start Date*: 2007-11-08
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg B...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10020160 HIV disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) PT (Completed) GB (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000813-19 Sponsor Protocol Number: EURE-CART-1 Start Date*: 2019-09-04
    Sponsor Name:MolMed S.p.A.
    Full Title: A Phase I-IIa trial to assess the safety and antitumor activity of autologous CD44v6 CAR T-cells in acute myeloid leukemia and multiple myeloma expressing CD44v6.
    Medical condition: Acute myeloid leukemia and Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005843-21 Sponsor Protocol Number: KT-US-982-5968 Start Date*: 2022-02-08
    Sponsor Name:KITE PHARMA INC.
    Full Title: Long-term Follow-up Study for Participants of Kite Sponsored Interventional Studies Treated With Gene-Modified Cells
    Medical condition: B-cell malignancies and Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008977 Chronic lymphocytic leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008978 Chronic lymphocytic leukemia refractory LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060558 Acute myeloid leukemia recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081514 Acute myeloid leukemia refractory LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063621 Acute lymphoblastic leukaemia recurrent LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006599 Burkitt's lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036714 Primary mediastinal large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000717-20 Sponsor Protocol Number: CD-TCR-002 Start Date*: 2019-10-09
    Sponsor Name:Medigene AG
    Full Title: Long-Term Follow-Up Clinical Trial of Subjects Treated with PRAME TCR modified T cells, MDG1011
    Medical condition: High Risk Myeloid and Lymphoid Neopolasms
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061240 Malignant lymphoid neoplasm PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028557 Myeloid leukemia, acute LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 12:15:32 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA